

## Percutaneous Coronary Interventions in the Diabetic Patient Where Do We Stand?

John A. Bittl, MD

Clinical observations made during the past 20 years have suggested that patients with diabetes mellitus (DM) have suboptimal outcomes after percutaneous coronary interventions (PCIs).<sup>1-4</sup> During the same time period, mechanistic studies have provided insights into the cardiovascular risk of DM. In this report, we attempt to synthesize observations made in the experimental laboratory with those made in the clinical setting to identify how diabetic traits may compromise the success of PCI (Figure 1).

### Pathogenetic Mechanisms of Diabetic Traits That May Compromise PCI Success

The hallmarks of DM are hyperglycemia, insulin resistance or an absolute lack of endogenous insulin, and hyperinsulinemia. These metabolic derangements may lead to premature atherosclerosis, cardiomyocyte dysfunction, and renal failure through several mechanisms.

### Diabetic Arteriopathy

In an early stage of atherogenesis, the presence of cholesterol crystals may induce the formation of small hydroxyapatite mineral clefts, which are also called microcalcifications, in the intima or media.<sup>5</sup> In DM, medial calcification develops independently of hypercholesterolemia and may cause sheet-like calcific deposits that reduce vascular compliance.<sup>6</sup> In the presence of hyperglycemia, medial calcification may be mediated by a glycosylation process, in which N-acetylglucosamine (O-GlcNAc) binds to serine and threonine residues of vascular proteins.<sup>7</sup> In a drug-induced mouse model of type 1 DM, Heath et al<sup>6</sup> found a strong increase in vascular O-GlcNAcylation after the onset of increased blood glucose levels, along with a significant increase in aortic calcium content and vascular stiffness. The connection between O-GlcNAcylation and the development of a mineralized matrix was confirmed in an experimental model of vascular smooth muscle cells cultured in osteogenic differentiation media along with an inhibitor of N-acetylglucosaminidase.<sup>6</sup>

The formation of vulnerable atherosclerotic lesions may be related to hyperglycemia<sup>8</sup> or insulin resistance.<sup>9</sup> Kuroda et al<sup>8</sup> observed that daily glucose fluctuations, measured as the mean amplitude of glycemic excursion, correlated with the volume percentage of necrotic core within 165 lesions,

as assessed by virtual histology intravascular ultrasound. In the analysis, the investigators observed that mean amplitude of glycemic excursion was the only independent predictor for the development of thin-cap fibroatheromas,<sup>8</sup> which have been associated with spontaneous plaque rupture and ischemic clinical events.<sup>10</sup> The role of mean amplitude of glycemic excursion in causing restenosis or neoatherosclerosis within stented segments remains unknown.

### Myocardial Dysfunction

Emerging evidence has identified a potential molecular link between insulin resistance and cardiomyopathy. The FoxO group of transcription factors that regulate cell size, viability, and metabolism are targets of insulin and growth factor signaling.<sup>11</sup> In a state of insulin resistance induced either genetically or by means of a high-fat diet in mice, the FoxO proteins are activated in cardiomyocytes and linked to the development of cardiomyopathy.<sup>11</sup> Cardiomyocyte-specific deletions of FoxO1 are associated with improvements in cardiac function when compared with native controls fed a high-fat diet.<sup>11</sup> Although the findings suggested that FoxO activation is an important factor in the pathogenesis of diabetic cardiomyopathy in the absence of coronary artery disease (CAD), a similar mechanism may contribute to ventricular dysfunction in the presence of obstructive CAD as well.

### Chronic Kidney Disease

Hyperglycemia contributes to diabetic nephropathy, a microvascular complication of DM, initially by causing glomerulomegaly and later by inducing mesangial expansion, glomerular basement membrane thickening, and glomerular sclerosis.<sup>12</sup> Like DM, chronic kidney disease is associated with the macrovascular complication of medial calcification. The process may be triggered by hyperphosphatemia and involve the formation of macrophage-derived matrix vesicles.<sup>5</sup> In an experimental model, New et al<sup>5</sup> observed that complexes containing phosphatidylserine, annexin V, and S100 calcium-binding protein A9 are formed in the presence of calcium and phosphate within macrophage-derived matrix vesicles and facilitate hydroxyapatite nucleation, contributing to vascular microcalcification.

Received December 1, 2014; accepted February 12, 2015.

From the Munroe Heart and Vascular Institute, Munroe Regional Medical Center, Ocala, FL.

Correspondence to John A. Bittl, MD, Munroe Heart and Vascular Institute, Munroe Regional Medical Center, 1221 SE 5th St, Ocala, FL 34471. E-mail jabittl@mac.com

(*Circ Cardiovasc Interv.* 2015;8:e001944. DOI: 10.1161/CIRCINTERVENTIONS.114.001944.)

© 2015 American Heart Association, Inc.

*Circ Cardiovasc Interv* is available at <http://circinterventions.ahajournals.org>

DOI: 10.1161/CIRCINTERVENTIONS.114.001944

### Altered Antiplatelet Pharmacokinetics

Patients with DM have an impaired response to clopidogrel, but it has been unclear whether this is caused by altered metabolism or an upregulation of the platelet-membrane P2Y<sub>12</sub> receptor. Using a comprehensive pharmacokinetic and pharmacodynamic approach, Angiolillo et al<sup>13</sup> observed that the active metabolites of clopidogrel were significantly lower in diabetic patients than in nondiabetic patients after a load of 600 mg. The findings suggested that the impaired responsiveness of diabetic patients to clopidogrel is caused by the pharmacokinetic profile of the drug and less so by an alteration in the functional status of the P2Y<sub>12</sub> signaling pathway.

### Exogenous Insulin

Premature CAD is common in DM, but it has been difficult to identify a relationship between hyperinsulinemia and atherogenesis. Clinical studies have suggested that glucose control in type 1 DM often requires exogenous insulin in amounts far greater than that secreted by normal  $\beta$ -cells and that endogenous hyperinsulinemia of type 2 DM is associated with increased hepatic synthesis of cholesterol and triglycerides.<sup>14</sup> Wang et al<sup>15</sup> investigated the relationship between hyperinsulinemia and hepatic markers of atherogenesis in a mouse model of type 1 DM. Although they observed that insulin injection significantly raised the plasma levels of proprotein convertase subtilisin/kexin type 9, an enzyme that cleaves the low-density lipoprotein receptor and thus raises low-density lipoprotein, the rise in proprotein convertase subtilisin/kexin type 9 levels did not exceed that of nondiabetic mice with lower insulin levels. In contrast, insulin injection in diabetic mice appeared to trigger the release of the proinflammatory mediators, tumor necrosis factor- $\alpha$  and interleukin-1 $\beta$ , from macrophages to levels higher than that seen in nondiabetic mice. The observations, which suggest that exogenous insulin promotes proinflammatory macrophage responses independent of markers of hepatic cholesterol processing,<sup>15</sup> may help explain the earlier clinical finding that inflammatory markers are increased in coronary atherectomy specimens obtained from diabetic patients.<sup>16</sup>

### Clinical Trial Results

The association between premature CAD and DM has been known for >35 years,<sup>17</sup> and suboptimal outcomes after PCI for the diabetic population have been known for >20 years.<sup>1,2</sup> Clinical trials completed during the past 20 years comprise an evidence base of comparisons of PCI with medical therapy (MT) or coronary artery bypass graft (CABG) surgery in patients with DM.

### PCI Versus MT in Diabetic Patients With Stable Ischemic Heart Disease


In the diabetic subgroup of the COURAGE trial, which comprised 33% of all randomized patients, no advantage of PCI over MT was seen for the composite primary outcome of death from any cause or nonfatal myocardial infarction (MI) during 4.6 years of follow-up (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.73–1.32).<sup>18</sup>

In BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes),<sup>19</sup> patients who underwent PCI had similar rates of major adverse cardiac events as those treated with MT, including nonfatal MIs (11.3% versus 10.2%). In a separate but higher risk stratum, patients treated with CABG had significantly fewer major cardiac events than those treated with MT, a finding that was driven mainly by a reduction in nonfatal MIs (7.4% versus 14.6%). BARI 2D was not designed to compare PCI with CABG.

### Clinical Trials Comparing PCI With CABG

After the seminal report from the first Bypass Angioplasty Revascularization Investigation (BARI), which described a 3-fold higher mortality rate 5 years after percutaneous transluminal coronary angioplasty than after CABG (20.6% versus 5.8%;  $P=0.0003$ ),<sup>3</sup> several observational studies and randomized clinical trials (RCTs) have reported outcomes in diabetic subgroups. Although some studies suggested equivalent outcomes, none has suggested a survival advantage of PCI (Table).

The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial reported no significant difference in mortality after PCI compared with



**Figure 1.** Diabetic traits potentially compromising the success of percutaneous coronary intervention.

CABG in the diabetic subgroup at 5 years (19.5% versus 12.9%;  $P=0.065$ ).<sup>43</sup> The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial, a dedicated RCT of 1900 diabetic patients with multivessel CAD, reported a higher rate of the composite of all-cause death, MI, or stroke after PCI than after CABG (26.6% versus 18.7%;  $P=0.005$ ), which was driven by higher rates of MI (13.9% versus 6.0%,  $P<0.001$ ) and death from any cause at 5 years (16.3% versus 11.0%;  $P=0.049$ ).<sup>45</sup>

### Clinical Guidelines

A systematic overview (Figure 2) suggests that diabetic patients with multivessel CAD enrolled in 9 RCTs have had higher mortality rates after PCI than after CABG at 5 years or the longest follow-up (odds ratio, 1.86; 95% CI, 1.32–2.63). Because only 3 of 9 RCTs reported mortality differences that were statistically significant (Figure 2)<sup>3,31,45</sup> and because the mortality difference in FREEDOM was statistically borderline,<sup>45</sup> the treatment benefit of CABG over PCI has remained uncertain. A Bayesian approach (Figure 3)<sup>48</sup> can be used to update what was previously known in early trials (prior distribution) with what is learned from FREEDOM (likelihood) to produce a new inference (posterior distribution) that supports the Class I recommendation proposed by the major cardiac societies favoring CABG over PCI to improve survival in diabetics with multivessel CAD requiring revascularization.<sup>51,52</sup>

### Which Diabetic Patients Should Get PCI?

Survival is not the only important outcome; so, we must not hold PCI or CABG in diabetic patients to a higher standard than revascularization for other indications. Relief of ischemic symptoms is another important goal. For diabetic patients in current practice who remain symptomatic despite optimal MT or who have substantial ischemia and severe CAD, PCI may be appropriate. In particular, diabetic patients with stable ischemic heart disease, focal disease, and a low SYNTAX score of  $\leq 22$  can be offered PCI as an alternative to CABG,<sup>52</sup> given

the favorable long-term outcomes reported for this subgroup treated with PCI<sup>43</sup> and a lower risk of stroke after PCI than after CABG (2.4% versus 5.2%,  $P=0.03$ ).<sup>45</sup>

### Acute Coronary Syndromes

Neither BARI 2D<sup>19</sup> nor COURAGE<sup>18</sup> demonstrated a survival advantage of PCI over MT, but both studies enrolled low-risk patients. Diabetic patients with acute coronary syndrome and focal disease may benefit from early revascularization with PCI.<sup>52</sup> Diabetic patients with multivessel CAD and acute coronary syndrome refractory to MT should probably have urgent or emergency PCI for the culprit lesion and a Heart Team consultation to discuss whether MT, PCI, or CABG would be most suitable for the remaining significant obstructive CAD.<sup>51</sup> For most diabetic patients with extensive multivessel CAD, particularly if the proximal segment of the left anterior descending coronary artery is involved and a left internal mammary graft can be used, CABG is the preferred method of revascularization based on evidence from clinical studies (Table).<sup>51,52</sup>

### ST-Segment–Elevation MI

Diabetic patients presenting with ST-segment–elevation MI and suitable anatomy should have PCI of the culprit lesion. If multivessel CAD is present, culprit-lesion PCI should be performed, followed by a Heart Team consultation to discuss whether MT, PCI, or CABG would be most suitable for remaining significant obstructive CAD.<sup>52</sup> If cardiogenic shock complicates ST-segment–elevation MI, multivessel PCI with or without hemodynamic support may be considered as an option to hemodynamic support and emergency CABG.<sup>53</sup>

### Specific Challenges in Diabetic Patients Who Need Revascularization

Although RCTs are helpful for making broad treatment recommendations, they cannot identify fine mechanistic details. A discussion of trial results, viewed against a background of

**Table. Evidence for Survival Benefit in Diabetic Patients With Stable Ischemic Heart Disease Who Are Receiving MT and Are Suitable Candidates for Revascularization With Either CABG Surgery or PCI**


| Evidence Supporting CABG for Survival Over MT | Evidence Supporting PCI for Survival Over MT | Evidence Supporting Superiority of Either CABG or PCI for Survival  | Evidence Supporting Equivalence of CABG and PCI for Survival  |
|---|--|---|---|
| For: Sorajja et al <sup>20*</sup>             | For: none                                    | CABG better: BARI <sup>3,21†</sup> ; Bair et al <sup>22</sup> unadjusted*; Brenner et al <sup>23*</sup> ; Deb et al <sup>24</sup> for SYNTAX score $>22$ ; Hlatky et al <sup>25†</sup> ; Javaid et al <sup>26*</sup> ; Malenka et al <sup>27*</sup> ; Niles et al <sup>28*</sup> ; Pell et al <sup>29</sup> for 3-V CAD*; SoS <sup>30†</sup> ; VA CARDS <sup>31†</sup> ; Verma et al <sup>4†</sup> ; and Weintraub et al <sup>32†</sup> | ARTS <sup>33†</sup> ; ARTS II <sup>34*</sup> ; Bair et al <sup>22</sup> adjusted*; Bangalore et al <sup>35†</sup> ; Barsness et al <sup>36*</sup> ; Bravata et al <sup>37†</sup> ; CARDia <sup>38†</sup> ; Daemen et al <sup>39†</sup> ; Deb et al <sup>24</sup> for SYNTAX score $\leq 22$ †; Dzavik et al <sup>40*</sup> ; MASS II <sup>41†</sup> ; Pell et al <sup>29</sup> for 2-V CAD*; and SYNTAX <sup>42,43†</sup> |
| No benefit: BARI 2D <sup>19†</sup>            | No benefit: BARI 2D <sup>19†</sup>           | PCI better: none  |   |

2-V CAD indicates 2-vessel coronary artery disease; 3-V CAD, 3-vessel coronary artery disease; ARTS, Arterial Revascularization Therapies Study; BARI, Bypass Angioplasty Revascularization Investigation; BARI 2D, Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary artery bypass graft; CARDia, Coronary Artery Revascularization in Diabetes; DM, diabetes mellitus; ERACI II, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease II; MASS II, Medicine, Angioplasty, or Surgery Study Part II; MT, medical therapy; PCI, percutaneous coronary intervention; SoS, Stent or Surgery; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; and VA CARDS, Veterans Administration Coronary Artery Revascularization in Diabetes. Reprinted from Levine et al<sup>44</sup> with permission of the publisher. Copyright ©2011, American College of Cardiology Foundation/American Heart Association.

\*Observational studies.

†Randomized controlled trials.

‡Meta-analyses.



**Figure 2.** Forest plot of mortality risk after coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disease. Original analyses were created with [R] 3.0.2,<sup>46</sup> using library package “meta” 3.8-0.<sup>47</sup> BARI indicates Bypass Angioplasty Revascularization Investigation; CARDia, Coronary Artery Revascularization in Diabetes; CI, confidence interval; ERACI II, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease II; FREEDOM, Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease; MASS II, Medicine, Angioplasty, or Surgery Study Part II; OR, odds ratio; SoS, Stent or Surgery; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; and VA CARDS, Veterans Administration Coronary Artery Revascularization in Diabetes.

known pathogenetic mechanisms (Figure 1), may explain some of the limitations of PCI and identify approaches to improve outcomes in diabetic patients who need revascularization.

### Diabetic Arteriopathy and PCI Outcomes

Two factors that compromise long-term success after PCI are high rates of restenosis and the development of vulnerable plaques outside stented segments. Almost all trials enrolling diabetic patients, including FREEDOM at 1 year (12.6% versus 4.8%;  $P<0.001$ ),<sup>45</sup> have reported higher rates of repeat revascularization after PCI than after CABG. Likewise, as in FREEDOM (13.9% versus 6.0%;  $P<0.001$ ),<sup>45</sup> most studies of diabetic patients have reported higher rates of MI after PCI than after CABG. These findings suggest that bypass conduits in diabetic patients provide better protection against the future development of clinically important lesions in longer segments of the coronary tree than does spot treatment with stents, despite the theoretical drawback of anastomosing bypass conduits to poor targets in small diabetic vessels.<sup>54</sup>

A hallmark of diabetic arteriopathy is medial calcification. Although it is difficult to quantify angiographically,<sup>55</sup> coronary calcification may be associated with suboptimal outcomes after PCI. A recent study suggested, however, that DM itself (HR, 2.10; 95% CI, 1.56–2.83) was a stronger independent predictor of all-cause mortality 1 year after PCI than was lesion calcification (HR, 1.10; 95% CI, 0.81–1.48).<sup>56</sup> The use of adjunctive ablative therapies for diabetic patients with calcified lesions has undergone limited investigation. In an uncontrolled trial of orbital atherectomy for patients with severely calcified lesions, 36.1% had DM and appeared to have acceptable procedural success rates,<sup>57</sup> but an earlier overview of randomized trials suggested that the routine use of ablative therapies does not improve long-term outcomes compared with standard approaches during PCI.<sup>58</sup> Additional studies are needed to compare ablative therapies with standard approaches for diabetic patients with calcified lesions.

A major advance in interventional cardiology has been the development of drug-eluting stents. Bangalore et al<sup>55</sup> reported that survival after implantation of platinum–chromium everolimus-eluting stents might be no different from that after CABG in diabetic patients with multivessel disease. It is important to recognize, however, in the absence of a survival advantage with each successive improvement in stent design in the general population of patients undergoing PCI,<sup>59,60</sup> that survival after spot treatment with everolimus-eluting stents would be unlikely to match the survival rate after CABG in diabetic patients in a prospectively designed randomized trial.


### Heart Failure

Many diabetic patients have heart failure, with or without systolic dysfunction. The presence of systolic dysfunction and multivessel CAD generally favors a recommendation of CABG over PCI to improve survival,<sup>44,61</sup> but the disadvantage of PCI in this setting has not been fully understood. A recent study suggested that a left ventricular ejection fraction of  $<40\%$  is a risk factor for ST (adjusted odds ratio, 2.25; 95% CI, 1.09–4.70).<sup>62</sup>

### Chronic Kidney Disease

Patients with chronic kidney disease have been under-represented in clinical trials. In BARI 2D and FREEDOM, patients were excluded if serum creatinine exceeded 2 mg/dL.<sup>19,45</sup> Like DM,<sup>6</sup> chronic kidney disease is associated both with medial calcification and suboptimal outcomes after PCI.<sup>63</sup> In patients with advanced renal failure with or without DM, a recent study found that CABG was associated with a 2- to 3-fold higher risk of causing acute kidney injury in the short term than was PCI,<sup>64</sup> but other studies have found that CABG was associated with a greater survival benefit in the long term.<sup>63</sup> Although current data might be more robust for CABG than for PCI in observational studies of patients with chronic kidney disease and multivessel CAD,<sup>44</sup> no dedicated RCTs have been completed in this patient population.





**Figure 3.** Bayesian triplot of mortality risk after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery in diabetic patients with multivessel coronary artery disease. The figure, which illustrates the way that Bayesian methods combine information from various sources, contains 3 plots on the familiar odds ratio (OR) scale as well as on the  $\theta$ , or  $\log_e(\text{OR})$ , scale. The prior distribution (gray), which is represented by a bell-shaped curve to show the distribution of all possible ORs based on evidence from 8 older trials,<sup>3,30,31,33,38,41,43,49</sup> strongly favors CABG. The likelihood (solid black), which represents the OR obtained from Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM),<sup>45</sup> still favors CABG but less so than the prior. Bayesian methods combine the likelihood with the prior in a type of meta-analysis to produce the posterior distribution (dotted black). The resulting bell-shaped curve is not twice the height of the prior or the likelihood because precision represented by probability density is additive. The most obvious difference between traditional frequentist and Bayesian methods is that frequentist statistics uses only the likelihood, whereas Bayesian statistics uses both the likelihood and the prior information. The posterior distribution (dotted black) confirms that there is a 95% probability that the mortality risk is 1.41 to 2.09 $\times$  higher after PCI than after CABG, with a mode at 1.72 (data labels). Original analyses were created with [R] 3.0.2,<sup>46</sup> using a normal conjugate model.<sup>48,50</sup> All curves are normalized to 1.

### Altered Pharmacokinetics

Given the impaired metabolism of clopidogrel in diabetic patients, many investigators have performed subgroup analyses of RCTs to evaluate alternative P2Y12 inhibitors. In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON TIMI 38),<sup>65</sup> lower rates of cardiovascular death, nonfatal MI, or nonfatal stroke were seen with prasugrel than with clopidogrel in patients with DM (12.2% versus 17.0%), without DM (9.2% versus 10.6%), and without increased major bleeding (2.6% versus 2.5%).

In the Platelet Inhibition and Patient Outcomes (PLATO) trial,<sup>66</sup> lower rates of all-cause mortality (HR, 0.82; 95% CI, 0.66–1.01) and stent thrombosis (HR, 0.65; 95% CI, 0.36–1.17) were seen with ticagrelor than with clopidogrel, without increased major bleeding (HR, 0.95; 95% CI, 0.81–1.12). In this study, the absence of P2Y12 blocker therapy was the strongest predictor of ST, and the presence of DM itself was a major risk factor for ST (adjusted odds ratio, 1.82; 95% CI, 1.02–3.24).<sup>62</sup>

Although the 2011 PCI guideline did not specify a preference of one P2Y12 agent over another,<sup>44</sup> the more potent

agents might be considered in diabetic patients undergoing PCI. Clinicians should recognize, however, that the potent P2Y12 receptor antagonists are not a panacea without complications, contraindications, or cost.<sup>67</sup> Patients with DM will continue to have a higher risk of ischemic events than patients without DM, apart from the P2Y12 antagonist used.<sup>65,66</sup>

### Glycemic Control

Several analyses have related poor outcomes after revascularization with the use of exogenous insulin.<sup>43,68</sup> Using data from the FREEDOM trial, Dangas et al<sup>45</sup> observed that the composite rate of death, MI, or stroke was higher in insulin-treated patients than in diabetic patients not treated with insulin. Moreover, the comparative advantage of CABG over PCI in lowering the primary end point was seen both in insulin-treated patients (24.3% versus 32.2%) and in diabetic patients not requiring insulin (15.6% versus 23.2%).<sup>68</sup> A time-to-event analysis suggested that cardiovascular risk was related to the duration of DM, with event rates being higher in patients with DM of duration  $\geq 9$  years than in those with DM of duration  $< 9$  years.<sup>68</sup> These results suggest, but do not prove, that CABG is favored over PCI for insulin-dependent or long-term diabetics.<sup>43,68</sup> On the other hand, an analysis of the survival curves suggests that PCI is favored over CABG for patients with a limited prognosis of  $< 3$  years because the event curves in the FREEDOM trial did not begin to separate and favor CABG over PCI until 2 to 4 years after revascularization.<sup>45</sup>

In several studies of MT with or without revascularization, tight glycemic control was unhelpful or associated with increased cardiovascular events.<sup>69–71</sup> In the Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation (ADVANCE), there was no significant effect of the type of glucose control on major macrovascular events (HR, 0.94; 95% CI, 0.84–1.06), death from cardiovascular causes (HR, 0.88; 95% CI, 0.74–1.04), or death from any cause (HR, 0.93; 95% CI, 0.83–1.06).<sup>72</sup>

### Insulin Sensitization

Insulin sensitization, as tested in BARI 2D most frequently with metformin (74.6%) or a thiazolidinedione (62.1%), did not improve the primary end point of freedom from major cardiovascular events (77.7% in the insulin sensitization group versus 75.4% in the insulin provision group;  $P=0.13$ ).<sup>19</sup> However, on the basis of results from the earlier UK Prospective Diabetes Study, metformin continues to be favored over the sulfonylureas to reduce cardiovascular complications in patients with DM.<sup>73</sup>

### Conclusions

Interventional cardiologists currently have a different perspective about treating diabetic patients with PCI than they had in 1997 when the BARI substudy was published.<sup>3</sup> Current evidence suggests that the development of vulnerable lesions, impaired left ventricle function, altered thienopyridine metabolism, renal failure, and the use of exogenous insulin impair the response to PCI. To optimize outcomes after

PCI or CABG in diabetic patients, physicians recognize that a revascularization procedure is one component of a comprehensive strategy involving cardiac rehabilitation, blood pressure control, smoking cessation, statins for lipid lowering, and angiotensin-converting enzyme inhibitors to prevent renal failure; but many challenges remain. Using PCI to treat patients with DM will become better understood and develop into a logical science if additional research can elucidate the molecular links between the metabolic derangements and the clinical manifestations of DM and if dedicated clinical trials continue to inform best practices.

## Disclosures

None.

## References

- Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Kantterud GL; TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patients subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II. *Circulation*. 1992;85:1254–1264.
- Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *Circulation*. 1996;94:1818–1825.
- The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation*. 1997;96:1761–1769.
- Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, Sud S, Gupta M, Singh S, Gupta N, Cheema AN, Leiter LA, Fedak PW, Teoh H, Latter DA, Fuster V, Friedrich JO. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2013;1:317–328. doi: 10.1016/S2213-8587(13)70089-5.
- New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, Libby P, Shanahan CM, Croce K, Aikawa E. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. *Circ Res*. 2013;113:72–77. doi: 10.1161/CIRCRESAHA.113.301036.
- Heath JM, Sun Y, Yuan K, Bradley WE, Litovsky S, Dell'Italia LJ, Chatham JC, Wu H, Chen Y. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. *Circ Res*. 2014;114:1094–1102. doi: 10.1161/CIRCRESAHA.114.302968.
- Rogers MA, Aikawa E. Modifying vascular calcification in diabetes mellitus: contribution of O-GlcNAcylation. *Circ Res*. 2014;114:1074–1076. doi: 10.1161/CIRCRESAHA.114.303684.
- Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y, Sugiyama D, Nakagawa M, Hariki H, Inoue T, Osue T, Taniguchi Y, Iwasaki M, Nichio R, Kinutani H, Konishi A, Hiranuma N, Takahashi H, Terashita D, Kirata K-i. Impact of daily glucose fluctuation on coronary plaque vulnerability in patients pretreated with lipid-lowering therapy: a prospective observations study. *J Am Coll Cardiol Interv*. In press.
- Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, Yoshida T, Arai K, Yokoi K, Ando H, Kumagai S, Ishii H, Izawa H, Hotta N, Murohara T. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. *JACC Cardiovasc Imaging*. 2008;1:39–45. doi: 10.1016/j.jcmg.2007.09.003.
- Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011;364:226–235. doi: 10.1056/NEJMoa1002358.
- Battiprolu PK, Hojaye B, Jiang N, Wang ZV, Luo X, Iglewski M, Shelton JM, Gerard RD, Rothermel BA, Gillette TG, Lavandero S, Hill JA. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. *J Clin Invest*. 2012;122:1109–1118. doi: 10.1172/JCI60329.
- Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA; Renal Pathology Society. Pathologic classification of diabetic nephropathy. *J Am Soc Nephrol*. 2010;21:556–563. doi: 10.1681/ASN.2010010010.
- Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. *J Am Coll Cardiol*. 2014;64:1005–1014. doi: 10.1016/j.jacc.2014.06.1170.
- Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. *Proc Natl Acad Sci U S A*. 2010;107:16009–16012. doi: 10.1073/pnas.1006639107.
- Wang MY, Yu X, Lee Y, McCorkle SK, Clark GO, Strowig S, Unger RH, Raskin P. Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers. *J Diabetes Complications*. 2013;27:70–74. doi: 10.1016/j.jdiacomp.2012.08.008.
- Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. *Circulation*. 2000;102:2180–2184.
- Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *JAMA*. 1979;241:2035–2038.
- Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356:1503–1516. doi: 10.1056/NEJMoa070829.
- The BARI 2D Study Group. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med*. 2009;360:2503–2515.
- Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. *Circulation*. 2005;112(9 suppl):I311–I316. doi: 10.1161/CIRCULATIONAHA.104.525022.
- The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med*. 1996;335:217–225.
- Bair TL, Muhlestein JB, May HT, Meredith KG, Horne BD, Pearson RR, Li Q, Jensen KR, Anderson JL, Lappé DL. Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry. *Circulation*. 2007;116(11 suppl):I226–I231. doi: 10.1161/CIRCULATIONAHA.106.681346.
- Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. *Circulation*. 2004;109:2290–2295. doi: 10.1161/01.CIR.0000126826.58526.14.
- Deb S, Wijeyesundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. *JAMA*. 2013;310:2086–2095. doi: 10.1001/jama.2013.281718.
- Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet*. 2009;373:1190–1197. doi: 10.1016/S0140-6736(09)60552-3.
- Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, Roy PK, Hill P, Okabe T, Torguson R, Smith KA, Xue Z, Gevorkian N, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. *Circulation*. 2007;116(11 suppl):I200–I206. doi: 10.1161/CIRCULATIONAHA.106.681148.

27. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, Helm RE, Kellett MA, Dauerman HL, Dacey LJ, Silver MT, VerLee PN, Weldner PW, Hettleman BD, Olmstead EM, Piper WD, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation*. 2005;112(9 suppl):I371–I376. doi: 10.1161/CIRCULATIONAHA.104.526392.
28. Niles NW, McGrath PD, Malenka D, Quinton H, Wennberg D, Shubrooks SJ, Tryzelaar JF, Clough R, Hearne MJ, Hernandez F Jr, Watkins MW, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. *J Am Coll Cardiol*. 2001;37:1008–1015.
29. Pell JP, Pell AC, Jeffrey RR, Jennings K, Oldroyd K, Eteiba H, Hogg KJ, Murday A, Faichney A, Colquhoun I, Berg G, Starkey IR, Flapan A, Mankad P. Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study of 6320 procedures. *Diabet Med*. 2004;21:790–792. doi: 10.1111/j.1464-5491.2004.01171.x.
30. The SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet*. 2002;360:965–970.
31. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King S III, Colling C, Moritz T, Stroupe K, Reda D; VA CARDS Investigators. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. *J Am Coll Cardiol*. 2013;61:808–816. doi: 10.1016/j.jacc.2012.11.044.
32. Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB III. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. *J Am Coll Cardiol*. 1998;31:10–19.
33. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. *Circulation*. 2001;104:533–538.
34. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, Sheiban I, Suttorp MJ, Vranckx P, Rademaker T, Goedhart D, Schuijjer M, Wittebols K, Macours N, Stoll HP, Serruys PW; ARTS-II Investigators. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. *J Am Coll Cardiol*. 2008;52:1957–1967. doi: 10.1016/j.jacc.2008.09.010.
35. Bangalore S, Toklu B, Feit F. Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: Can newer generation drug-eluting stents bridge the gap? *Circ Cardiovasc Interv*. 2014;7:18–25. doi: 10.1161/CIRCINTERVENTIONS.114.001346.
36. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. *Circulation*. 1997;96:2551–2556.
37. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. *Ann Intern Med*. 2007;147:703–716.
38. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol*. 2010;55:432–440. doi: 10.1016/j.jacc.2009.10.014.
39. Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, Rodriguez-Granillo G, Hueb WA, Lemos PA, Serruys PW. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. *Circulation*. 2008;118:1146–1154. doi: 10.1161/CIRCULATIONAHA.107.752147.
40. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, Galbraith PD, Hui W, Faris P, Knudtson ML; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. *Am Heart J*. 2001;142:119–126. doi: 10.1067/mhj.2001.116072.
41. Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, Jatene F, Pereira AC, Góis AF, Oliveira SA, Ramires JA. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. *Ann Thorac Surg*. 2007;83:93–99. doi: 10.1016/j.athoracsur.2006.08.050.
42. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. *J Am Coll Cardiol*. 2010;55:1067–1075. doi: 10.1016/j.jacc.2009.09.057.
43. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg*. 2013;43:1006–1013. doi: 10.1093/ejcts/ezt017.
44. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011;124:e574–e565. doi: 10.1161/CIR.0b013e31823ba622.
45. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S III, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med*. 2012;367:2375–2384. doi: 10.1056/NEJMoa1211585.
46. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2013.
47. Schwarzer G. *Package 'Meta' Version 3.8-0*. Freiburg, Germany; 2012.
48. Lang CD, He Y, Bittl JA. Bayesian inference supports the use of bypass surgery over percutaneous coronary intervention to reduce mortality in diabetic patients with multivessel coronary disease. *Int J Stat Med Res*. 2015;4:26–34.
49. Rodriguez AE, Baldi J, Fernández Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, Vigo F, Vogel D, O'Neill W, Palacios IF; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). *J Am Coll Cardiol*. 2005;46:582–588. doi: 10.1016/j.jacc.2004.12.081.
50. Spiegelhalter DJ, Abrams KR, Myles JP. *Bayesian Approaches to Clinical Trials and Health Care Evaluations*. Chichester, England: Wiley; 2004.
51. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2014;130:1749–1767. doi: 10.1161/CIR.0000000000000095.
52. Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Lauger G, Neuman FJ, Richter DJ, Shauer P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association



- for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014;35:2541–2619. doi: 10.1093/eurheartj/ehu278.
53. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-segment myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127:529–555. doi: 10.1161/CIR.0b013e3182742c84.
  54. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM; Bypass Angioplasty Revascularization Investigation. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation*. 2002;106:2652–2658.
  55. Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. *J Am Coll Cardiol*. 2014;63:1703–1714. doi: 10.1016/j.jacc.2014.01.017.
  56. Généreux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, Lasalle L, Xu K, McAndrew T, Kirtane A, Lansky AJ, Brener SJ, Mehran R, Stone GW. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *J Am Coll Cardiol*. 2014;63:1845–1854. doi: 10.1016/j.jacc.2014.01.034.
  57. Chambers JW, Feldman RL, Himmelstein SI, Bhatheja R, Villa AE, Strickman NE, Shlofmitz RA, Dulas DD, Arab D, Khanna PK, Lee AC, Ghali MG, Shah RR, Davis TP, Kim CY, Tai Z, Patel KC, Puma JA, Makam P, Bertolet BD, Nseir GY. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). *JACC Cardiovasc Interv*. 2014;7:510–518. doi: 10.1016/j.jcin.2014.01.158.
  58. Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. *J Am Coll Cardiol*. 2004;43:936–942. doi: 10.1016/j.jacc.2003.10.039.
  59. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttrop MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med*. 2007;356:1030–1039. doi: 10.1056/NEJMoa067484.
  60. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. *Lancet*. 2009;373:911–918. doi: 10.1016/S0140-6736(09)60319-6.
  61. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med*. 2008;358:331–341. doi: 10.1056/NEJMoa071804.
  62. Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignallou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. *JAMA*. 2011;306:1765–1774. doi: 10.1001/jama.2011.1529.
  63. Chan W, Ivanov J, Ko D, Fremes S, Rao V, Jolly S, Cantor WJ, Lavi S, Overgaard CB, Ruel M, Tu JV, Džavík V. Clinical outcomes of treatment by percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with chronic kidney disease undergoing index revascularization in Ontario. *Circ Cardiovasc Interv*. 2015;8:e001973. doi: 10.1161/CIRCINTERVENTIONS.114.001973.
  64. Chang TI, Leong TK, Boothroyd DB, Hlatky MA, Go AS. Acute kidney injury after CABG versus PCI: an observational study using 2 cohorts. *J Am Coll Cardiol*. 2014;64:985–994. doi: 10.1016/j.jacc.2014.04.077.
  65. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. *Circulation*. 2008;118:1626–1636. doi: 10.1161/CIRCULATIONAHA.108.791061.
  66. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. *J Am Coll Cardiol*. 2010;31:3006–3016. doi: 10.1093/eurheartj/ehq325.
  67. Price MJ. Diabetes mellitus and clopidogrel response variability. *J Am Coll Cardiol*. 2014;64:1015–1018. doi: 10.1016/j.jacc.2014.07.003.
  68. Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, Abizaid A, Buller CE, Devlin G, Rodriguez AE, Lansky AJ, Siami FS, Domanski M, Fuster V; FREEDOM Investigators. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. *J Am Coll Cardiol*. 2014;64:1189–1197. doi: 10.1016/j.jacc.2014.06.1182.
  69. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med*. 2009;151:394–403.
  70. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campagne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care*. 2009;32:381–386. doi: 10.2337/dc08-1671.
  71. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360:129–139. doi: 10.1056/NEJMoa0808431.
  72. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre G, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompont S, de Galan BE, Joshi R, Travert F; The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–2572.
  73. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352:854–865.

KEY WORDS: angioplasty, balloon, coronary ■ coronary artery disease ■ diabetes mellitus ■ stents



## Percutaneous Coronary Interventions in the Diabetic Patient: Where Do We Stand? John A. Bittl

*Circ Cardiovasc Interv.* 2015;8:e001944

doi: 10.1161/CIRCINTERVENTIONS.114.001944

*Circulation: Cardiovascular Interventions* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2015 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://circinterventions.ahajournals.org/content/8/4/e001944>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Cardiovascular Interventions* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation: Cardiovascular Interventions* is online at:  
<http://circinterventions.ahajournals.org/subscriptions/>